Unibest

管线数据库

UB275

Imipenem and Cilastatin Sodium for Injection

提交项目新药候选物数据库

UB275

ProductImipenem and Cilastatin Sodium for Injection
Strength0.25g: 0.25g; 0.5g: 0.5g
IndicationsBacterial infection; Mixed infection; Peritonitis; Hepatobiliary infection; Intra-abdominal abscess; Appendicitis; Female genital tract infection; Lower respiratory tract infection; Skin and soft tissue infection; Urinary tract infection; Osteomyelitis; Septic arthritis; Sepsis
TherapeuticsInfectious Diseases
GMPCN - NMPA
RegistrationChina
ModalitiesSmall Molecule

Exclusive Summary

  • - Fully off-patent and widely genericized worldwide, enabling rapid entry via distribution into hospital tenders and shortage backfills
  • - On WHO Essential Medicines List and in AWaRe Watch group; endorsed by IDSA and other guidelines for severe ESBL infections, HAP/VAP, and cIAI
  • - Serves high-burden critical-care needs (≈48.9M sepsis cases and 11M related deaths annually; HAI prevalence 7–10%), with AMR trends sustaining demand
  • - Dual SKUs (0.25/0.25 and 0.5/0.5) support pediatric/renal-adjusted dosing and pharmacy stewardship across departments
  • - Despite crowded competition, 70–90% price discount vs originator plus reliable supply (Zone IVb stability, dedicated β-lactam sterile line, robust CTD) can win tenders in emerging markets

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →